TCGA-NC-A5HL-01A-11R-A26W-07
— · cohortSQ2
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortSQ2
- subtype
- cohortSQ2
- age_years
- 73
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.490
- E2F_TARGETS+0.330
- INTERFERON_ALPHA_RESPONSE+0.280
- MTORC1_SIGNALING+0.280
- APICAL_SURFACE+0.240
- G2M_CHECKPOINT+0.220
- INTERFERON_GAMMA_RESPONSE+0.210
- ALLOGRAFT_REJECTION+0.190
- MYC_TARGETS_V1+0.190
- KRAS_SIGNALING_DN+0.140
Top 10 suppressed
- TGF_BETA_SIGNALING-0.490
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.440
- UV_RESPONSE_DN-0.370
- ANDROGEN_RESPONSE-0.330
- ANGIOGENESIS-0.310
- COAGULATION-0.310
- PEROXISOME-0.300
- KRAS_SIGNALING_UP-0.280
- FATTY_ACID_METABOLISM-0.240
- PROTEIN_SECRETION-0.240
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-BH-A0B9-01A-11R-A056-07 | — | E | 0.868 |
| 2 | SRR650176 | — | — | 0.859 |
| 3 | SRR650177 | — | — | 0.846 |
| 4 | fcfc55a0-35e6-4fae-a599-66af11ba856d | — | — | 0.834 |
| 5 | TCGA-A2-A4S3-01A-21R-A266-07 | — | B | 0.826 |
| 6 | ULC0564T_S96 | — | cohortA1 | 0.820 |
| 7 | s0112318 | — | — | 0.814 |
| 8 | SRR8518141 | — | E | 0.812 |
| 9 | SRR11296816 | — | — | 0.810 |
| 10 | TCGA-OL-A5D7-01A-11R-A27Q-07 | — | E | 0.806 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.490 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.330 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.280 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.280 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.240 | Temsirolimus | — uncovered |
| G2M_CHECKPOINT | 0.220 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.210 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.190 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.190 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.140 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.120 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.100 | Idelalisib | — uncovered |
| UV_RESPONSE_UP | 0.100 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.040 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.040 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.040 | Idelalisib | — uncovered |
| MITOTIC_SPINDLE | 0.020 | Inavolisib | — uncovered |